Aberrant pulmonary vascular growth and remodeling are frequently seen in bronchopulmonary dysplasia (Alvira, 2016), and the fibroblast growth factor (FGF)-2 and VEGF are promising targets in the treatment of respiratory disorders (Laddha and Kulkarni, 2019). Here, FGF2 is linked to bronchopulmonary dysplasia.